Amarin Corporation plc (AMRN)

NCM – Real Time Price. Currency in USD

14.92

-0.02 (-0.13%)

Market open: May 13, 2026, 11:44 AM EDT

08.05.2026

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

05.05.2026

All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy

Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

29.04.2026

Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript

29.04.2026

Amarin Reports 2026 First Quarter Financial Results

Total Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global Medical Society Endorsements Supporting the Use of Icosapent Ethyl (IPE) in Contemporary Lipid and Cardiovascular Risk Management DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the first quarter ended March 31, 2026 (Q1 2026).

23.04.2026

Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?

Here is how Amarin (AMRN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.

15.04.2026

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET.

07.03.2026

Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks

Amarin has one drug, and it has lost key patent protections. The company is cutting costs in an effort to generate positive cash flow.

Videos

No Data

There is no data to display

Press releases

29.04.2026

Amarin Reports 2026 First Quarter Financial Results

23.02.2026

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

DUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to action for American Heart Month emphasizing a message that cannot wait: the United States has an opportunity to significantly reduce heart attacks, strokes, and cardiovascular deaths by prioritizing the use of proven, existing therapies that are widely available, yet significantly underutilized.

09.01.2026

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in therapies for patients with elevated triglycerides (TG) and shared its perspective on how these developments stand to shape patient access and treatment strategies. Specifically, new therapies for these patients are likely to expand the use of existing, proven options over time, including Amarin's VASCEPA®/VAZKEPA® (icosapent ethyl), an effective, safe, oral therapy that has been prescribed more than 25 million times to patients globally. In addition, through its approved indication for severe hypertriglyceridemia (sHTG), which is defined as TG ≥500 mg/dL, as well as strong clinical evidence, affordability, and broad reimbursement, VASCEPA/VAZKEPA aligns with current payor-driven step therapy programs, which require patients to try existing safe and efficacious treatment options before newer, more expensive sHTG alternatives.

09.11.2025

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the importance of guideline-directed therapies and further validate the role of icosapent ethyl in comprehensive CV risk management in appropriate patients as studied in REDUCE-IT. This analysis was presented soon after the U.S. Food and Drug Administration (FDA) updated labeling for fenofibrate (fibrates) products that now include language on the neutral PROMINENT trial, reinforcing the lack of CV benefit when fibrates were used alongside statins for cardiovascular risk reduction; a pivotal moment that underscores the need for more effective, evidence-based approaches to residual CV risk.

Amarin Corporation plc (AMRN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Amarin Corporation plc (AMRN)

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy

Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript

Amarin Reports 2026 First Quarter Financial Results

Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks

Videos

No Data

Press releases

Amarin Reports 2026 First Quarter Financial Results

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy

Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript

Amarin Reports 2026 First Quarter Financial Results

Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks

Videos

No Data

Press releases

Amarin Reports 2026 First Quarter Financial Results

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Search stocks

Amarin Corporation plc (AMRN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Amarin Corporation plc (AMRN)

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy

Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript

Amarin Reports 2026 First Quarter Financial Results

Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks

Videos

No Data

Press releases

Amarin Reports 2026 First Quarter Financial Results

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy

Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript

Amarin Reports 2026 First Quarter Financial Results

Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks

Videos

No Data

Press releases

Amarin Reports 2026 First Quarter Financial Results

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients